Kalohexis 710GO data puts melanocortin obesity drugs back in the metabolic spotlight
GLP-1 drugs dominate obesity care, but Kalohexis is testing a different pathway. 710GO could shift the next weight loss race.
Could Caliway’s CBL-514 become a metabolic add-on to semaglutide and tirzepatide?
GLP-1 drugs drive weight loss, but rebound and body composition gaps remain. Caliway’s CBL-514 may test the next obesity frontier.
Can Currax and Peek make oral obesity treatment easier to access for self-funded employers?
Currax expands Contrave access through PeekDirect. Read what this could mean for obesity drug pricing, employers, and non-GLP-1 treatment adoption.
Can Novo Nordisk’s semaglutide 7.2 mg set a new standard in obesity treatment?
Novo Nordisk’s semaglutide 7.2 mg achieves 20.7% weight loss. Find out what this EU regulatory step means for obesity treatment and patient outcomes in 2026.